Altasciences is proud to announce the completion of a second expansion of its ligand binding laboratory to meet the high demand for quality bioanalytical services. The GLP, GCP laboratory was enlarged to include 52 benches for sample analysis, an enhanced space for cell culture and flow cytometry services, additional extraction rooms for handling all types of tissue matrices, a dedicated CL2 room for handling samples and RG2 material, a balance room for critical reagent and solution preparation, and an extraction space for an additional 50 analysts.

With this expansion, Altasciences’ ligand binding assay tripled its square footage and will add to its employee base. Altasciences’ goal is to offer clients the opportunity to leverage the significant knowledge and industry experience of its team of scientific experts to develop strategic bioanalytical testing plans to complement its drug development programs.

Altasciences uses innovative and cost-effective approaches to develop or customize ligand binding assays for the quantitative determination of biologics and small molecules therapeutic products. Altasciences continues to expand its immunogenicity, PK, oligonucleotide and biomarker testing to its already robust preclinical and clinical trial and bioanalysis testing capabilities.

Click here to have a look at the new lab expansion.
 

Have a question? Speak with an expert today.

Altasciences is a forward-thinking, mid-size contract research organization offering pharmaceutical and biotechnology companies a proven, flexible approach to preclinical and clinical pharmacology studies, including formulation, manufacturing, and analytical services. For over 25 years, Altasciences has been partnering with sponsors to help support educated, faster, and more complete early drug development decisions. Altasciences’ integrated, full-service solutions include preclinical safety testing, clinical pharmacology and proof of concept, bioanalysis, program management, medical writing, biostatistics, clinical monitoring, and data management, all customizable to specific sponsor requirements. Altasciences helps sponsors get better drugs to the people who need them, faster.
 

As your drug development partner, we have a deep appreciation of both the challenges and the potential of your small molecule. At Altasciences, we understand why developing your molecule requires tailored solutions at every stage. 

Find out how our small molecule solutions help identify new and improved approaches to study designs, and anticipate development challenges as studies evolve. 

Bring us your challenge. We have the solution.

Challenge us

You may also be interested in the following:

• Factsheet: Small Molecule Safety Assessment
• IND/CTA Guide: Planning your Preclinical Assessment
• Webpage: Bioanalytical Services

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether for a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.

One of the most significant milestones in drug development research is the transition from preclinical to clinical studies. Ensuring risk mitigation at all steps of preclinical and clinical testing, as well as incorporating a thorough safety review plan in the clinical setting, is integral. 

Altasciences applies recommendations from world-wide regulatory agencies to ensure that studies are conducted safely, ethically, and in a scientifically robust manner.

We facilitate drug development and save you time by:

1. Preparing your preclinical study designs, including species selection and dose level determination.
2. Conducting the required safety testing and updating your Investigational Brochure while your IND/CTA-enabling studies are in progress.
3. Writing your IND/CTA applications.
4. Planning your clinical program while your preclinical safety assessment is ongoing so that you can initiate your first-in-human (FIH) trials as soon as you receive regulatory approval.
5. Designing your FIH clinical protocol using preclinical study data, including identifying the maximum safe starting doses.
6. Timing small-scale drug formulations with clinical conduct to get your trials started sooner.
7. Conducting your FIH trials and making quick, informed dosing decisions based on timed bioanalytical data and safety data available within 48 hours.
8. Quickly identifying trial findings that may allow you to waive certain studies or provide critical data for safety/dosing considerations in subsequent clinical studies.  

Our preclinical, manufacturing, bioanalytical, and clinical teams work closely together to transition drugs through the critical early phases of drug development.

Speak with our experts.

You may also be interested in the following:

• Video: Your Road to Proactive Drug Development with Altasciences
• Webpage: Scientific, Regulatory and Strategic Guidance
• Webpage: Full-Time Equivalent (FTE) Capabilities

Altasciences transforms the traditional outsourcing paradigm by simplifying and streamlining solutions, whether a single study or multiple programs, to offer an integrated/synchronized approach to CRO and CDMO services from lead candidate selection to clinical proof of concept, and beyond.